News & Updates

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

Unique features characterize the occurrence of heat-related illnesses, such as cramps, exhaustion, and stroke, among patients admitted to the emergency department (ED) of Singapore General Hospital, reports a recent study.